NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Hyperopia,

I certainly respect your opinion. I don't know about your figures on the CAR-T approved drug, but I know a great deal of CAR-T work is being done experimentally by many, I suspect that many needing it are in trials and therefore don't pay for it.

I know that multi-millions are normally invested in commercial production equipment for most new drugs. CAR-T is another special case product, but I find it hard to believe that Novartis couldn't make more than that if the demand was there. I believe the demand for DCVax-L will be so great that the FDA will be strongly criticized if supply is dramatically insufficient. Perhaps all the company needs to do is provide a plan to meet the demand once approved, but I've seen the FDA turn down approvals when they deemed manufacturing was inadequate.

Gary